Purpose: To determine the ef® cacy and toxicity of docetaxel as ® rst-line chem otherapy in adult patients with locally advanced and/or metastatic soft tissue sarcoma (STS). Patients/ m ethods. Thirty eligible patients, with histologically proven STS, Eastern Cooperative Oncology Group (EC OG) performance status 0± 2 and bidimensionally measurable disease, entered this study. None had received previous chem otherapy. Docetaxel 100 m g m 2 2 was given as a 1-h intravenous infusion every 3 weeks. Patients were evaluable for response, evaluated by W HO criteria, after one cycle of chem otherapy and toxicity was graded by NCIC-CT G comm on toxicity criteria. Results. One hundred and thirty two cycles were aldministered, with a range per patient of 1± 9. The m edian delivered dose intensity was 32.2 mg m 2 2 week 2 1 (planned 33.3 mg m 2 2 week 2 1 ) and 67% of patients received $ 90% planned dose intensity. There were three partial responses (10.7% ; 95% con® dence interval 2.3± 28.2) with a median duration of 7 months (range 6.4± 8.3 months). Thirty patients were evaluable for non-haematological toxicity and 28 for haematological toxicity (repeat counts were not available in two patients). Haematological toxicity was moderately severe, with 18 (64% ) patients experiencing at least one episode of grade 4 neutropenia, and 7 (25%) patients experiencing febrile neutropenia. C onclusio ns. In this study, activity of docetaxel in adult chem otherapy-naõ È ve patients with advanced STS was modest K ey w ords: docetaxel, chem otherapy, soft tissue sarcom a
Introduction
In the past 10 years, there has been little progress in the m anagement of m etastasized soft tissue sarcom a (ST S). A m inority of patients have long-term bene® t from resection of lung m etastases. 1 N o new active agents have been identi® ed since doxorubicin and dacarbazine in the 1970s, and ifosfam ide in the m id-1980s. 2 D espite encouraging data from singlearm studies, random ized trials have failed to demonstrate convincingly the superiority of com bination chem otherapy 3 com pared with single-agent doxorubicin. Sim ilarly, dose intensi® cation of standard agents or regim ens, which have produced prom ising response rates in pilot studies, have not been proven m ore active in random ized trials. 4 The need for active new agents is clear.
To optim ize the possibility of identifying new active drugs for this disease, the Canadian Sarcom a G roup working with the N C IC C linical Trials G roup has pursued for several years, a policy of offering investigational drug treatment to chem otherapy-naõ È ve patients, with the option to proceed to standard drugs if initial treatment fails.
D ocetaxel (Taxotere) is a sem i-syn thetic analogue of paclitaxel, prepared using a precursor extracted from the needles of the E uropean yew, Taxus baccata. 5 By enhancing m icrotubule assem bly and inhibiting depolym erization of tubulin, docetaxel causes accum ulation of m icrotubules in the cell and, by blocking cells in the M -phase of the cell cycle, prevents cell division. 6 Based on m ore potent in vivo antitum our activity com pared with paclitaxel, in B16 m elanom a and a variety of colon carcinom as, 7 as well as a favou rable toxicity pro® le in anim als, docetaxel w as selected for hum an studies. Com paring the toxicities observed in the ® ve hum an phase I trials, the highest m axim um tolerated dose (MT D ) and dose intensity were achieved with the 1-h 3-w eekly infusion schedule. 8 T he dose selected for this, and other phase II studies, was 100 m g m 2 2 . 9 /l, treatment was delayed until recovery. Haem atopoietic colony stim ulating factors were not used. If patients developed grade 3 peripheral neuropathy, they were taken off protocol therapy, and a dose reduction of 25% was applied for grade 2 neurotoxicity. For other toxic effects $ grade 3, drug administration was delayed until resolution to # grade 1, and then reinstituted with a dose reduction of 25%. O nce doses had been reduced for toxicity, they were not re-escalated.
Patient evaluation
Patients were evaluable for response after receiving one cycle of therapy (3 weeks on the study).
Responding patients continued on the study until evidence of disease progression, or the occurrence of unacceptable toxicity. Patients with com plete (C R) or partial (PR) response continued on therapy for a m axim um of four cycles after docum entation of response. Patients with stable disease (SD ) continued on therapy for a m axim um of six cycles. W H O criteria for response were em ployed and toxic effects w ere graded according to the N C IC -CT G comm on toxicity criteria.
Results
Between April 1994 and June 1995, 32 patients were enrolled from eight Canadian centres. T wo patients were ineligible: one had no measurable lesions and in the other the histology was not ST S. T wo further patients were not evaluable for response and haem atological toxicity. T he condition of one patient deteriorated suddenly w ith onset of congestive heart failure, renal failure and sepsis, and she died 6 days after the ® rst dose of docetaxel. T he second patient did not com plete the ® rst dose of docetaxel because of a severe hypersensitivity reaction and went off study. Table 1 Table 2 ). F ebrile neutropenia was reported in seven (25% ) patients. Two other patients had a docum ented grade 4 infection not thought to be related to therapy. In 30 evaluable patients, the m ost frequently observed non-haem atological toxicities thought to be drug related were alopecia (77% ), lethargy (60% ), sensory neuropathy (43% ), oedema (27%), nausea (33%), vom iting (27% ), anorexia (23%) and diarrhoea (40% ), but m ost of these were m ild (Table 3) .
In 28 evaluable patients, there were three PRs (10.7% ; 95% con® dence interval (CI) 2.3± 28.2% ) w ith a m edian duration of 7 months (range 6.4± 8.3 m onths). Thirteen patients had lasting 5.4 m onths (range 2.1± 20.9 m onths). T he m edian num ber of cycles received by these patients was six (range 3± 14) . Two of the PRs occurred in patients with leiom yosarcom a (one uterine, one retroperitoneal), the m ost com m on histological type entered into the study. T he third response occurred in a patient with m alignant ® brous histiocytom a. T wo of the responses occurred in lung m etastases, and the third in a retroperitoneal m ass.
D iscussion
The taxanes, paclitaxel and docetaxel, are a new class of cytotoxic drugs with activity in a variety of solid tumours. Paclitaxel was the ® rst analogue to be tested, and was shown to be active in platinum-resistant ovarian cancer 9 and also in breast cancer. 10 A dif® cult extraction process, from the bark of the Paci® c yew, initially limited supplies and accelerated the search for semi-synthetic analogues, such as docetaxel. In phase II trials, docetaxel has shown signi® cant activity, w ith reproducible response rates of greater than 20% , in breast cancer, non-sm all cell lung, ovarian , gastric, squam ous head and neck and bladder cancers. 11 Both analogues have been evaluated in advanced/ m etastatic ST S. T here have been two studies of paclitaxel at a dose of 250 m g m 2 2 every 3 weeks.
In the larger South W est O ncology Group (SW O G) study 12 , there was one C R and 5 PRs for an overall every 3 weeks, all of whom had received previous chem otherapy. These encouraging results prom pted the EO RTC to undertake a random ized phase III study com paring 100 m g m 2 2 every 3 weeks of docetaxel with 75 m g m 2 2 every 3 weeks of doxorubicin. T his study has just been reported in abstract form . 16 W ith 86 patients on study and 73 available for analysis, the prelim inary response rates were 0% for docetaxel and 27% for doxorubicin, the latter being very sim ilar to previous EO RT C experience w ith single-agent doxorubicin. The current study was started shortly after publication in abstract form 17 of the preliminary results of the EORT C phase II study describing, at that time, ® ve PRs (21.7% ) in 23 patients. W e hoped to con® rm , and perhaps im prove on, these results in chem otherapy-n aõ È ve patients. The low response rate seen in our study w as surprising, but is less so now that it is seen in the context of the m ore recent EO RTC phase III results. 16 It is intriguing that in a different tum our type, sm all-cell lung cancer, a higher response rate of 25% 18 was seen in previously treated patients receiving docetaxel, com pared with 8% 19 in a second study including only chemotherapy-naõ È ve patients. As the EO RTC study 17 includes a cross-ove r com ponent this m ay provide further data on this issue. Thirteen patients achieved SD . Rapidly progressive disease at entry was not a protocol requirement, but m ost Canadian oncologists use chemotherapy in the setting of progressive sym ptom atic m etastatic disease, and this disease stabilization m ay be an additional indicator of drug activity.
It has been suggested that leiom yosarcom as, particularly those of bowel m etastatic to liver, are less responsive to chem otherapy. However, leiom yosarcom as (including those of gastrointestinal origin now known as strom al tum ours) m ay com prise onethird to one-half of tum ours in clinical trials of m etastatic STS. T his is true of our study (39% ), the phase II 15 and III 17 studies of the EO RTC (41%; 36% ) and for the SW OG 12 and W altzm an studies 13 of paclitaxel, 54% and 53% respectively. This sim ilar distribution does not provide a reason for the discrepant response rates. T he m ost likely explanation is chance occurrence in sm all patient populations.
Conclusions
D espite initial prom ise, data from this study, and m ore recent phase II and III studies, do not suggest that taxanes have m ajor activity in adult ST S.
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